Cargando…
PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke
Background: Stroke is a significant public health problem and a leading cause of death and long-term disability worldwide. Several treatments for ischemic stroke have been developed, but these treatments have limited effectiveness. One potential treatment for this condition is Actovegin(®)/AODEJIN,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295843/ https://www.ncbi.nlm.nih.gov/pubmed/37371718 http://dx.doi.org/10.3390/biomedicines11061623 |
_version_ | 1785063517171220480 |
---|---|
author | Anghelescu, Aurelian Firan, Florentina Carmen Onose, Gelu Munteanu, Constantin Trandafir, Andreea-Iulia Ciobanu, Ilinca Gheorghița, Ștefan Ciobanu, Vlad |
author_facet | Anghelescu, Aurelian Firan, Florentina Carmen Onose, Gelu Munteanu, Constantin Trandafir, Andreea-Iulia Ciobanu, Ilinca Gheorghița, Ștefan Ciobanu, Vlad |
author_sort | Anghelescu, Aurelian |
collection | PubMed |
description | Background: Stroke is a significant public health problem and a leading cause of death and long-term disability worldwide. Several treatments for ischemic stroke have been developed, but these treatments have limited effectiveness. One potential treatment for this condition is Actovegin(®)/AODEJIN, a calf blood deproteinized hemodialysate/ultrafiltrate that has been shown to have pleiotropic/multifactorial and possibly multimodal effects. The actual actions of this medicine are thought to be mediated by its ability to reduce oxidative stress, inflammation, and apoptosis and to enhance neuronal survival and plasticity. Methods: To obtain the most up-to-date information on the effects of Actovegin(®)/AODEJIN in ischemic stroke, we systematically reviewed the literature published in the last two years. This review builds upon our previous systematic literature review published in 2020, which used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method to search for and select related articles over almost two decades, between 1 January 2001 and 31 December 2019. Additionally, we compared the results of our PRISMA search (human intelligence-based) with those obtained from an interrogation of a GPT-based chatbot (ChatGPT) in order to ensure comprehensive coverage of potentially relevant studies. Results: Our updated review found limited new evidence on the use of Actovegin(®)/AODEJIN in ischemic stroke, although the number of articles on this subject consistently increased compared to that from our initial systematic literature review. Specifically, we found five articles up to 2020 and eight more until December 2022. While these studies suggest that Actovegin(®)/AODEJIN may have neuroprotective effects in ischemic stroke, further clinical trials are needed to confirm these findings. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Discussion: Our funnel analysis showed no evidence of publication bias, suggesting that the limited number of studies identified was not due to publication bias but rather due to a lack of research in this area. However, there are limitations when using ChatGPT, particularly in distinguishing between truth and falsehood and determining the appropriateness of interpolation. Nevertheless, AI can provide valuable support in conducting PRISMA-type systematic literature reviews, including meta-analyses. Conclusions: The limited number of studies identified in our review highlights the need for additional research in this area, especially as no available therapeutic agents are capable of curing central nervous system lesions. Any contribution, including that of Actovegin (with consideration of a positive balance between benefits and risks), is worthy of further study and periodic reappraisal. The evolving advancements in AI may play a role in the near future. |
format | Online Article Text |
id | pubmed-10295843 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102958432023-06-28 PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke Anghelescu, Aurelian Firan, Florentina Carmen Onose, Gelu Munteanu, Constantin Trandafir, Andreea-Iulia Ciobanu, Ilinca Gheorghița, Ștefan Ciobanu, Vlad Biomedicines Systematic Review Background: Stroke is a significant public health problem and a leading cause of death and long-term disability worldwide. Several treatments for ischemic stroke have been developed, but these treatments have limited effectiveness. One potential treatment for this condition is Actovegin(®)/AODEJIN, a calf blood deproteinized hemodialysate/ultrafiltrate that has been shown to have pleiotropic/multifactorial and possibly multimodal effects. The actual actions of this medicine are thought to be mediated by its ability to reduce oxidative stress, inflammation, and apoptosis and to enhance neuronal survival and plasticity. Methods: To obtain the most up-to-date information on the effects of Actovegin(®)/AODEJIN in ischemic stroke, we systematically reviewed the literature published in the last two years. This review builds upon our previous systematic literature review published in 2020, which used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method to search for and select related articles over almost two decades, between 1 January 2001 and 31 December 2019. Additionally, we compared the results of our PRISMA search (human intelligence-based) with those obtained from an interrogation of a GPT-based chatbot (ChatGPT) in order to ensure comprehensive coverage of potentially relevant studies. Results: Our updated review found limited new evidence on the use of Actovegin(®)/AODEJIN in ischemic stroke, although the number of articles on this subject consistently increased compared to that from our initial systematic literature review. Specifically, we found five articles up to 2020 and eight more until December 2022. While these studies suggest that Actovegin(®)/AODEJIN may have neuroprotective effects in ischemic stroke, further clinical trials are needed to confirm these findings. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Discussion: Our funnel analysis showed no evidence of publication bias, suggesting that the limited number of studies identified was not due to publication bias but rather due to a lack of research in this area. However, there are limitations when using ChatGPT, particularly in distinguishing between truth and falsehood and determining the appropriateness of interpolation. Nevertheless, AI can provide valuable support in conducting PRISMA-type systematic literature reviews, including meta-analyses. Conclusions: The limited number of studies identified in our review highlights the need for additional research in this area, especially as no available therapeutic agents are capable of curing central nervous system lesions. Any contribution, including that of Actovegin (with consideration of a positive balance between benefits and risks), is worthy of further study and periodic reappraisal. The evolving advancements in AI may play a role in the near future. MDPI 2023-06-02 /pmc/articles/PMC10295843/ /pubmed/37371718 http://dx.doi.org/10.3390/biomedicines11061623 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Anghelescu, Aurelian Firan, Florentina Carmen Onose, Gelu Munteanu, Constantin Trandafir, Andreea-Iulia Ciobanu, Ilinca Gheorghița, Ștefan Ciobanu, Vlad PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
title | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
title_full | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
title_fullStr | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
title_full_unstemmed | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
title_short | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
title_sort | prisma systematic literature review, including with meta-analysis vs. chatbot/gpt (ai) regarding current scientific data on the main effects of the calf blood deproteinized hemoderivative medicine (actovegin) in ischemic stroke |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295843/ https://www.ncbi.nlm.nih.gov/pubmed/37371718 http://dx.doi.org/10.3390/biomedicines11061623 |
work_keys_str_mv | AT anghelescuaurelian prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT firanflorentinacarmen prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT onosegelu prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT munteanuconstantin prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT trandafirandreeaiulia prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT ciobanuilinca prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT gheorghitastefan prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT ciobanuvlad prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke |